Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review

• Published in: Zeitschrift für Rheumatologie Vol. 80; no. Suppl 1; pp. 1 - 9
• Main Authors: Fiehn, C., Ness, T., Weseloh, C., Specker, C., Hadjiski, D., Detert, J., Krüger, K.
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer Medizin 01-02-2021
• Subjects: Antimalarials - adverse effects; Antirheumatic Agents - adverse effects; Child; Empfehlungen und Stellungnahmen von Fachgesellschaften; Humans; Hydroxychloroquine - adverse effects; Immunology; Internal Medicine; Laboratory Medicine; Medicine; Medicine & Public Health; Orthopedics; Rheumatology; Safety Management; Hydroxychloroquin; Ophthalmologische Untersuchung; Retinopathie; Hydroxychloroquine; Retinopathy; Chloroquine; Lupus erythematodes; Lupus erythematosus; Chloroquin; Ophthalmological examination
• ISSN: 0340-1855; 1435-1250
• DOI: 10.1007/s00393-020-00785-4

Background
Antimalarial medication (AM) plays an important role in the treatment of rheumatic diseases.
Objective
Updated evidence-based recommendations on the safety management of rheumatological treatment with AM are presented.
Methods
A systematic literature search in the databases Medline (PubMed) and Cochrane identified 1160 studies on the safety of treatment with AM in rheumatology. In addition, a manual search was carried out and 67 publications considered to be particularly relevant by the authors were analyzed in more detail. These publications served as a basis for consensus-based recommendations.
Results
Treatment with AM in rheumatology should be carried out with hydroxychloroquine (HCQ) with a dosage not exceeding 5 mg/kg body weight/day. Patients should undergo a basic ophthalmological examination within the first 6 months of AM treatment. Pre-existing maculopathy, renal insufficiency (glomerular filtration rate, GFR <60 ml/min), tamoxifen comedication, a daily dose of >5 mg/kg HCQ or treatment with chloroquine (CQ) show an increased risk for AM-induced retinopathy. These patients should undergo an annual ophthalmological check from the beginning of the treatment, whereas patients with no risk factors are recommended to start this only after 5 years of taking the medication. The ophthalmological examination should comprise at least both an appropriate subjective and an objective method and these are usually an automated visual field test and optical coherence tomography (OCT). A visual field test revealing a parafoveal sensitivity loss and an OCT showing a parafoveal circumscribed loss of the photoreceptor layer or focal interruptions of the structural line of the outer segment are signs of a possible AM retinopathy. Determination of creatine kinase (CK) and lactate dehydrogenase (LDH) in blood is appropriate to screen for cardiomyopathy and myopathy and should be checked before starting the treatment and then ca. every 3 months. The use of cardiac biomarkers, such as brain natriuretic peptide (BNP) or troponin in serum, electrocardiograph (ECG) or cardiac imaging should be considered depending on the situation. An intake of HCQ is safe during pregnancy and breastfeeding according to the current state of knowledge and is protective for mother and child in patients with systemic lupus erythematosus.
Conclusion
The updated recommendations on AM treatment in rheumatology in particular include a more rigorous measuring of doses, risk stratification in monitoring and defined ophthalmological examination methods to detect a possible retinopathy.